PRFX
PainReform Ltd.
Drug Manufacturers - Specialty & Generic
Market Cap$862K
5Y Perf.-99.9%
Compare Stocks
2 / 10Try these comparisons:
Stock Comparison
PRFX vs XTLB
Revenue, margins, valuation, and 5-year total return — side by side.
XTLB
XTL Biopharmaceuticals Ltd.
Biotechnology
Market Cap$294K
5Y Perf.-64.9%
PRFX vs XTLB — Key Financials
Market cap, revenue, margins, and valuation side-by-side.
| Company Snapshot | PRFX | XTLB |
|---|---|---|
| Industry | Drug Manufacturers - Specialty & Generic | Biotechnology |
| Market Cap | $862K | $294K |
| Revenue (TTM) | $0.00 | $451K |
| Net Income (TTM) | $-4M | $-1M |
| Gross Margin | — | 26.4% |
| Operating Margin | — | -481.6% |
| Total Debt | $45K | $138K |
| Cash & Equiv. | $4M | $371K |
PRFX vs XTLB — Long-Term Stock Performance
Price return indexed to 100 at period start. Dividends excluded.
PRFX
XTLB
| Stock | Sep 20 | May 26 | Return |
|---|---|---|---|
| PainReform Ltd. (PRFX) | 100 | 0.1 | -99.9% |
| XTL Biopharmaceutic… (XTLB) | 100 | 35.1 | -64.9% |
Price return only. Dividends and distributions are not included.
Quick Verdict: PRFX vs XTLB
Each card shows where this stock fits in a portfolio — not just who wins on paper.
Bottom line: XTLB leads in 3 of 6 categories, making it the strongest pick for capital preservation and lower volatility and recent price momentum and sentiment. PainReform Ltd. is the stronger pick specifically for growth and revenue expansion and profitability and margin quality. As sector peers, any of these can serve as alternatives in the same allocation.
PRFX
PainReform Ltd.
The Growth Play
PRFX is the clearest fit if your priority is growth exposure and sleep-well-at-night.
- EPS growth 81.2%
- Lower volatility, beta 1.73, Low D/E 2.5%, current ratio 1.81x
- 77.9% revenue growth vs XTLB's -173.2%
Best for: growth exposure and sleep-well-at-night
XTLB
XTL Biopharmaceuticals Ltd.
The Income Pick
XTLB carries the broadest edge in this set and is the clearest fit for income & stability and long-term compounding.
- beta 1.71
- -87.3% 10Y total return vs PRFX's -99.9%
- Beta 1.71, current ratio 0.61x
Best for: income & stability and long-term compounding
See the full category breakdown
| Category | Winner | Why |
|---|---|---|
| Growth | PRFX | 77.9% revenue growth vs XTLB's -173.2% |
| Quality / Margins | PRFX | 1.9% margin vs XTLB's -227.7% |
| Stability / Safety | XTLB | Beta 1.71 vs PRFX's 1.73 |
| Dividends | Tie | Neither stock pays a meaningful dividend |
| Momentum (1Y) | XTLB | -50.9% vs PRFX's -82.1% |
| Efficiency (ROA) | XTLB | -17.7% ROA vs PRFX's -36.6% |
PRFX vs XTLB — Financial Metrics
Side-by-side numbers across 2 stocks — who leads on profitability, valuation, growth, and risk.
BEST OVERALLXTLBLAGGINGPRFX
PRFXPainReform Ltd.
1leads
XTLBXTL Biopharmaceutical…
4leads
6 Total Categories
CATEGORYLEADERvs PRFXMETRICS WON
Income & Cash FlowRevenue, margins, and cash flow strength
PRFX1/1
Valuation MetricsMultiples, price ratios, and targets
XTLB2/2
Profitability & EfficiencyROE, ROIC, leverage, and quality scores
XTLB5/8
Total Returns1Y, 3Y, 5Y total returns with dividends
XTLB6/6
Risk & VolatilityBeta, volatility, and downside exposure
XTLB2/2
Analyst OutlookRatings, price targets, and dividends
—
—
Income & Cash Flow (Last 12 Months)
PRFX leads this category, winning 1 of 1 comparable metric.
Income & Cash Flow (Last 12 Months)
XTLB and PRFX operate at a comparable scale, with $451,000 and $0 in trailing revenue.
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| RevenueTrailing 12 months | $0 | $451,000 |
| EBITDAEarnings before interest/tax | -$4M | -$1M |
| Net IncomeAfter-tax profit | -$4M | -$1M |
| Free Cash FlowCash after capex | -$6M | $0 |
| Gross MarginGross profit ÷ Revenue | — | +26.4% |
| Operating MarginEBIT ÷ Revenue | — | -4.8% |
| Net MarginNet income ÷ Revenue | — | -2.3% |
| FCF MarginFCF ÷ Revenue | — | -3.7% |
| Rev. Growth (YoY)Latest quarter vs prior year | — | — |
| EPS Growth (YoY)Latest quarter vs prior year | +98.9% | +20.0% |
PRFX leads this category, winning 1 of 1 comparable metric.
Valuation Metrics
XTLB leads this category, winning 2 of 2 comparable metrics.
Valuation Metrics
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Market CapShares × price | $861,734 | $293,767 |
| Enterprise ValueMkt cap + debt − cash | -$3M | $60,767 |
| Trailing P/EPrice ÷ TTM EPS | -0.06x | -0.28x |
| Forward P/EPrice ÷ next-FY EPS est. | — | — |
| PEG RatioP/E ÷ EPS growth rate | — | — |
| EV / EBITDAEnterprise value multiple | — | — |
| Price / SalesMarket cap ÷ Revenue | — | 0.65x |
| Price / BookPrice ÷ Book value/share | 0.47x | 0.05x |
| Price / FCFMarket cap ÷ FCF | — | — |
XTLB leads this category, winning 2 of 2 comparable metrics.
Profitability & Efficiency
XTLB leads this category, winning 5 of 8 comparable metrics.
Profitability & Efficiency
XTLB delivers a -25.5% return on equity — every $100 of shareholder capital generates $-26 in annual profit, vs $-48 for PRFX. PRFX carries lower financial leverage with a 0.02x debt-to-equity ratio, signaling a more conservative balance sheet compared to XTLB's 0.03x. On the Piotroski fundamental quality scale (0–9), XTLB scores 3/9 vs PRFX's 1/9, reflecting mixed financial health.
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| ROE (TTM)Return on equity | -48.4% | -25.5% |
| ROA (TTM)Return on assets | -36.6% | -17.7% |
| ROICReturn on invested capital | — | -54.1% |
| ROCEReturn on capital employed | -3.1% | -50.7% |
| Piotroski ScoreFundamental quality 0–9 | 1 | 3 |
| Debt / EquityFinancial leverage | 0.02x | 0.03x |
| Net DebtTotal debt minus cash | -$4M | -$233,000 |
| Cash & Equiv.Liquid assets | $4M | $371,000 |
| Total DebtShort + long-term debt | $45,000 | $138,000 |
| Interest CoverageEBIT ÷ Interest expense | -1048.07x | -13.31x |
XTLB leads this category, winning 5 of 8 comparable metrics.
Total Returns (Dividends Reinvested)
XTLB leads this category, winning 6 of 6 comparable metrics.
Total Returns (Dividends Reinvested)
A $10,000 investment in XTLB five years ago would be worth $1,963 today (with dividends reinvested), compared to $23 for PRFX. Over the past 12 months, XTLB leads with a -50.9% total return vs PRFX's -82.1%. The 3-year compound annual growth rate (CAGR) favors XTLB at -18.4% vs PRFX's -78.7% — a key indicator of consistent wealth creation.
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| YTD ReturnYear-to-date | -45.6% | +11.3% |
| 1-Year ReturnPast 12 months | -82.1% | -50.9% |
| 3-Year ReturnCumulative with dividends | -99.0% | -45.7% |
| 5-Year ReturnCumulative with dividends | -99.8% | -80.4% |
| 10-Year ReturnCumulative with dividends | -99.9% | -87.3% |
| CAGR (3Y)Annualised 3-year return | -78.7% | -18.4% |
XTLB leads this category, winning 6 of 6 comparable metrics.
Risk & Volatility
XTLB leads this category, winning 2 of 2 comparable metrics.
Risk & Volatility
XTLB is the less volatile stock with a 1.71 beta — it tends to amplify market swings less than PRFX's 1.73 beta. A beta below 1.0 means the stock typically moves less than the S&P 500. XTLB currently trades 26.0% from its 52-week high vs PRFX's 10.6% drawdown — a narrower gap to the peak suggests stronger recent price momentum.
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Beta (5Y)Sensitivity to S&P 500 | 1.73x | 1.71x |
| 52-Week HighHighest price in past year | $17.95 | $10.28 |
| 52-Week LowLowest price in past year | $0.77 | $1.05 |
| % of 52W HighCurrent price vs 52-week peak | +10.6% | +26.0% |
| RSI (14)Momentum oscillator 0–100 | 35.0 | 57.0 |
| Avg Volume (50D)Average daily shares traded | 622K | 2.4M |
XTLB leads this category, winning 2 of 2 comparable metrics.
Analyst Outlook
Insufficient data to determine a leader in this category.
Analyst Outlook
| Metric | PRFXPainReform Ltd. | XTLBXTL Biopharmaceut… |
|---|---|---|
| Analyst RatingConsensus buy/hold/sell | — | — |
| Price TargetConsensus 12-month target | — | — |
| # AnalystsCovering analysts | — | — |
| Dividend YieldAnnual dividend ÷ price | — | — |
| Dividend StreakConsecutive years of raises | — | — |
| Dividend / ShareAnnual DPS | — | — |
| Buyback YieldShare repurchases ÷ mkt cap | 0.0% | 0.0% |
Insufficient data to determine a leader in this category.
Key Takeaway
XTLB leads in 4 of 6 categories (Valuation Metrics, Profitability & Efficiency). PRFX leads in 1 (Income & Cash Flow).
Best OverallXTL Biopharmaceuticals Ltd. (XTLB)Leads 4 of 6 categories
Loading custom metrics...
PRFX vs XTLB: Frequently Asked Questions
6 questions · data-driven answers · updated daily
01Which is the better long-term investment — PRFX or XTLB?
Over the past 5 years, XTL Biopharmaceuticals Ltd.
(XTLB) delivered a total return of -80. 4%, compared to -99. 8% for PainReform Ltd. (PRFX). Over 10 years, the gap is even starker: XTLB returned -87. 3% versus PRFX's -99. 9%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.
02Which is safer — PRFX or XTLB?
By beta (market sensitivity over 5 years), XTL Biopharmaceuticals Ltd.
(XTLB) is the lower-risk stock at 1. 71β versus PainReform Ltd. 's 1. 73β — meaning PRFX is approximately 1% more volatile than XTLB relative to the S&P 500. On balance sheet safety, PainReform Ltd. (PRFX) carries a lower debt/equity ratio of 2% versus 3% for XTL Biopharmaceuticals Ltd. — giving it more financial flexibility in a downturn.
03Which has better profit margins — PRFX or XTLB?
PainReform Ltd.
(PRFX) is the more profitable company, earning 0. 0% net margin versus -227. 7% for XTL Biopharmaceuticals Ltd. — meaning it keeps 0. 0% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: PRFX leads at 0. 0% versus -481. 6% for XTLB. At the gross margin level — before operating expenses — XTLB leads at 0. 7%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.
04Which pays a better dividend — PRFX or XTLB?
None of the stocks in this comparison currently pay a material dividend.
All are effectively zero-yield and should be held for capital appreciation rather than income.
05Is PRFX or XTLB better for a retirement portfolio?
For long-horizon retirement investors, XTL Biopharmaceuticals Ltd.
(XTLB) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding. PainReform Ltd. (PRFX) carries a higher beta of 1. 73 — meaning larger drawdowns in market downturns, which matters significantly when you cannot wait years for a recovery. Both have compounded well over 10 years (XTLB: -87. 3%, PRFX: -99. 9%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.
06What are the main differences between PRFX and XTLB?
Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.
These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.
Find Stocks Like These
Explore pre-built screens for each stock's profile, or build a custom screen to find stocks that outperform both.
You Might Also Compare
Based on how these companies actually compete and overlap — not just which sector they're filed under.